Slide 1: CoStAR targeting folate receptor alpha enhances anti-tumour activity of TIL
A CD28/CD40-based chimeric costimulatory antigen receptor (CoStAR™) targeting folate receptor alpha enhances anti-tumour activity of tumour infiltrating lymphocytes. John Bridgeman PhD. Director Discovery Research Instil Bio TM TM Confidential Confidential
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation, including statements regarding our strategy, the preclinical and clinical devel
Slide 3: Executive Summary
Executive Summary Instil Bio has developed a platform technology called CoStAR 1 (Costimulatory Antigen Receptor) 2 CoStAR enhances the function of T cells and TIL in vitro and in vivo Currently being evaluated as ITIL-306 in human clinical trials with first patient 3 dosed 3 Confidential
Slide 4: Tumour Infiltrating Lymphocyte (TIL) Therapy
Tumour Infiltrating Lymphocyte (TIL) Therapy Cryopreservation Tumour infiltrating lymphocytes (TIL) & Infusion therapy depends upon: Surgical Resection 1. Isolating TIL from a patient tumours 2. Expanding them to high numbers ex Patient vivo in favourable growth conditions 3. Infusion back into the
Slide 5: The CoStAR (CoStimulatory Antigen Receptor) principle
The CoStAR (CoStimulatory Antigen Receptor) principle Non-transduced TIL CoStAR-transduced TIL • Low level cytokine secretion • Elevated cytokine secretion • Tumour killing • Enhanced tumour killing • Limited proliferative response • Increased proliferative response • Lack of costimulation leads to
Slide 6: ITIL-306 CoStAR Targets FRα
ITIL-306 CoStAR Targets FRα 300 FRα staining H-Score 250 200 150 100 50 0 NSCLC, Adeno. HGSOC ccRCC 6 Confidential
Slide 7: CoStAR enhances T cell effector function
CoStAR enhances T cell effector function 7 Confidential
Slide 8: CoStAR greatly enhances in vitro T cell proliferation
CoStAR greatly enhances in vitro T cell proliferation 8 Confidential
Slide 9: CoStAR is active in TIL from multiple indications
CoStAR is active in TIL from multiple indications Ovarian cancer Renal cancer Non-small cell lung cancer 9 Confidential
Slide 10: CoStAR enhances TIL activity towards autologous tumour
CoStAR enhances TIL activity towards autologous tumour Ovarian cancer Renal cancer Non-small cell lung cancer 10 Confidential
Slide 11: CoStAR Enhances the Function of T cells in vivo
CoStAR Enhances the Function of T cells in vivo 11 Confidential
Slide 12: CoStAR activity summary
CoStAR activity summary CoStAR-Td TIL FRα+ Normal tissue CoStAR-Td TIL FRα- Tumour • No effector activity • Low level cytokine secretion • Tumour killing • Limited proliferative response Non-Td TIL FRα+ Tumour CoStAR-Td TIL FRα+ Tumour • Low level cytokine secretion • Elevated cytokine secretion • T
Slide 13: Summary
Summary Instil Bio has developed a platform technology called CoStAR 1 (Costimulatory Antigen Receptor). 2 CoStAR enhances T cell effector function and proliferation in an IL-2 independent manner. CoStAR is strictly dependent on provision of signal 1, and is not activated by membrane 3 anchored or s
Slide 14: Thank you!
Thank you! John.bridgeman@instilbio.com www.instilbio.com Confidential Confidential